PDF(Pubmed)
Abstract：
BACKGROUND: Achalasia poses a significant socioeconomic burden, yet global trends remain undocumented. This study aims to describe the worldwide trends in the incidence and prevalence of achalasia from 1925 to 2021 and explore their correlation with various factors through a comprehensive systematic review.
METHODS: We searched the PubMed/MEDLINE, Embase, and Cochrane databases from inception to 30 June 2023, to identify studies reporting the incidence or prevalence of achalasia in the general population. This study utilized pooled estimates with 95% confidence intervals (CI) to estimate the incidence and prevalence of achalasia, and conducted various subgroup analyses.
RESULTS: A total of 26 eligible studies covering approximately 269 million participants and 20,873 patients from 14 countries across five continents were included. Global pooled incidence and prevalence of achalasia were estimated to be 0.78 cases per 100,000 person-years (95% CI, 0.64-0.93; number of studies, 26; sample population, 269,315,171) and 10.82 cases per 100,000 person-years (95% CI, 8.15-13.48; number of studies, 14; sample population, 192,176,076), respectively. The incidence of achalasia was higher in Oceania (than Asia and Africa) and in adults (than children) after the introduction of the Chicago classification. Prevalence followed a similar pattern. The pooled incidence of achalasia showed an overall upward trend from 1925 to 2021 (1925-1999; 0.40 [0.32-0.49] vs. 2018-2021; 1.64 [1.33-1.95] cases per 100,000 person-years).
CONCLUSIONS: The incidence and prevalence of achalasia have notably increased, particularly with advancements in diagnosis, and show significant variation worldwide, despite the large heterogeneity within the sample population. Further studies are necessary to accurately assess the global incidence and prevalence of achalasia.
METHODS: We searched the PubMed/MEDLINE, Embase, and Cochrane databases from inception to 30 June 2023, to identify studies reporting the incidence or prevalence of achalasia in the general population. This study utilized pooled estimates with 95% confidence intervals (CI) to estimate the incidence and prevalence of achalasia, and conducted various subgroup analyses.
RESULTS: A total of 26 eligible studies covering approximately 269 million participants and 20,873 patients from 14 countries across five continents were included. Global pooled incidence and prevalence of achalasia were estimated to be 0.78 cases per 100,000 person-years (95% CI, 0.64-0.93; number of studies, 26; sample population, 269,315,171) and 10.82 cases per 100,000 person-years (95% CI, 8.15-13.48; number of studies, 14; sample population, 192,176,076), respectively. The incidence of achalasia was higher in Oceania (than Asia and Africa) and in adults (than children) after the introduction of the Chicago classification. Prevalence followed a similar pattern. The pooled incidence of achalasia showed an overall upward trend from 1925 to 2021 (1925-1999; 0.40 [0.32-0.49] vs. 2018-2021; 1.64 [1.33-1.95] cases per 100,000 person-years).
CONCLUSIONS: The incidence and prevalence of achalasia have notably increased, particularly with advancements in diagnosis, and show significant variation worldwide, despite the large heterogeneity within the sample population. Further studies are necessary to accurately assess the global incidence and prevalence of achalasia.
摘要：
背景：失语症构成了巨大的社会经济负担，然而，全球趋势仍然没有记录。本研究旨在描述1925年至2021年全球门失弛缓症的发病率和患病率趋势，并通过全面的系统评价探讨其与各种因素的相关性。
方法：我们搜索了PubMed/MEDLINE，Embase,和Cochrane数据库从开始到2023年6月30日，以确定报告一般人群中门失弛缓症发生率或患病率的研究。这项研究使用了具有95％置信区间（CI）的汇总估计值来估计贲门失弛缓症的发生率和患病率。并进行了各种亚组分析。
结果：共纳入26项符合条件的研究，涵盖来自五大洲14个国家的约2.69亿参与者和20,873名患者。全球贲门失弛缓症的合并发病率和患病率估计为每100,000人年0.78例(95%CI,0.64-0.93;研究数量,26；样本人口，269,315,171)和10.82例/100,000人年(95%CI，8.15-13.48；研究数量，14；样本人口，192,176,076），分别。引入芝加哥分类后，大洋洲（比亚洲和非洲）和成人（比儿童）的门失弛缓症的发病率更高。患病率遵循类似的模式。从1925年到2021年，贲门失弛缓症的合并发病率总体呈上升趋势(1925-1999；0.40[0.32-0.49]vs.2018-2021年；每10万人年1.64例[1.33-1.95]例）。
结论：门失弛缓症的发病率和患病率明显增加，特别是随着诊断的进步，并在全球范围内显示出巨大的差异，尽管样本群体内存在很大的异质性。需要进一步的研究来准确评估门失弛缓症的全球发病率和患病率。
方法：我们搜索了PubMed/MEDLINE，Embase,和Cochrane数据库从开始到2023年6月30日，以确定报告一般人群中门失弛缓症发生率或患病率的研究。这项研究使用了具有95％置信区间（CI）的汇总估计值来估计贲门失弛缓症的发生率和患病率。并进行了各种亚组分析。
结果：共纳入26项符合条件的研究，涵盖来自五大洲14个国家的约2.69亿参与者和20,873名患者。全球贲门失弛缓症的合并发病率和患病率估计为每100,000人年0.78例(95%CI,0.64-0.93;研究数量,26；样本人口，269,315,171)和10.82例/100,000人年(95%CI，8.15-13.48；研究数量，14；样本人口，192,176,076），分别。引入芝加哥分类后，大洋洲（比亚洲和非洲）和成人（比儿童）的门失弛缓症的发病率更高。患病率遵循类似的模式。从1925年到2021年，贲门失弛缓症的合并发病率总体呈上升趋势(1925-1999；0.40[0.32-0.49]vs.2018-2021年；每10万人年1.64例[1.33-1.95]例）。
结论：门失弛缓症的发病率和患病率明显增加，特别是随着诊断的进步，并在全球范围内显示出巨大的差异，尽管样本群体内存在很大的异质性。需要进一步的研究来准确评估门失弛缓症的全球发病率和患病率。
